GLAXO Intraday Analysis...

Recommended Links

share price of punjab & sind bank jaiprakash associates share price nse mahindra & mahindra ltd share price share price of hindalco industries hdfc bank share price nse technocraft industries india ltd share price ceramic fuel cells share price share rate of vijaya bank sri renuka sugars share price aer lingus share price analysis leni oil and gas share price hotel leela share price today larsen and toubro share price future

GLAXO Share Price

Open 2450.75 Change Price %
High 2473.25 1 Day -10.55 -0.43
Low 2413.00 1 Week -12.00 -0.48
Close 2463.05 1 Month 19.00 0.78
Volume 12715 1 Year -293.80 -10.66
52 Week High 2798.50
52 Week Low 2201.20
GLAXO Important Levels
Resistance 2 2518.90
Resistance 1 2495.89
Pivot 2449.77
Support 1 2430.21
Support 2 2407.20
NSE INDIA Most Active Stocks
JPASSOCIAT 21.95 1.15%
RCOM 28.65 -2.72%
GMRINFRA 22.95 1.32%
VISESHINFO 0.25 -16.67%
UNITECH 8.95 -1.10%
ONGC 200.70 3.61%
AXISBANK 611.55 3.61%
ADANIPOWER 37.60 -1.18%
RELIANCE 971.50 4.32%
SUZLON 15.00 -0.66%
NSE INDIA Top Gainers Stocks
APOLLO 441.75 60.64%
OMAXAUTO 143.45 19.99%
AHLEAST 401.15 17.28%
VINYLINDIA 117.35 16.36%
DPSCLTD 33.70 13.28%
SOBHA 599.25 11.83%
KAMATHOTEL 151.05 11.48%
NATNLSTEEL 45.85 11.15%
SHEMAROO 550.55 10.40%
LINCOLN 261.40 10.09%
NSE INDIA Top Losers Stocks
VISESHINFO 0.25 -16.67%
GRUH 588.95 -14.37%
KSERASERA 0.30 -14.29%
NAKODA 0.45 -10.00%
DALMIASUG 107.45 -9.97%
UTTAMSUGAR 109.75 -8.69%
DWARKESH 41.15 -7.94%
AVADHSUGAR 720.25 -6.78%
RAJRAYON 0.70 -6.67%
SGL 19.15 -6.36%

GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO)

GLAXO Technical Analysis 3
As on 22nd Jan 2018 GLAXO Share Price closed @ 2463.05 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2513.14 & Sell for SHORT-TERM with Stoploss of 2489.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
GLAXO Target for January
1st Target up-side 2599.2
2nd Target up-side 2676.23
3rd Target up-side 2753.26
1st Target down-side 2379.4
2nd Target down-side 2302.37
3rd Target down-side 2225.34
GLAXO Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 48.22 Sideways
MFI (14) MFI is 39.76 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is -58.62 Sideways
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Short Sell 2529.90
10 Day Avg Volume Traded -16.82 % Less then 10 Day Average Volume
GLAXO Other Details
Segment EQ
Market Capital 94531387392.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website
GLAXO Address
Dr. Annie Besant Road
Mumbai, 400030
Phone: 91 22 2495 9595
Fax: 91 22 2495 9494
GLAXO Latest News
IPO Report: SteadyMed (STDY) - 20th Mar 15
Pharmaceutical, Biotech Mergers Set Record in 2014 Pharmaceutical Processing - 19th Mar 15
A Decade Old Drug Launch In China With Important Insights Today Forbes - 18th Mar 15
MGM and Black Diamond Are Big Market Movers New York Times - 17th Mar 15
Business news in brief - 14th Mar 15
India's Sun Pharma to buy GSK's opiates business in Australia Reuters - 03rd Mar 15
GSK Pharma to move cancer drug portfolio to Novartis arm - 12th Feb 15
GlaxoSmithKline Pharmaceuticals Ltd clarifies on CCI nod Equity Bulls - 26th Dec 14
CCI clears Novartis-GSK pharma deal - 23rd Dec 14
GlaxoSmithKline Pharmaceuticals Announces Q3 Results Business Wire India (press release) - 06th Nov 14
Interactive Technical Analysis Chart GlaxoSmithKline Pharmaceuticals Limited ( GLAXO NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on GlaxoSmithKline Pharmaceuticals Limited
GLAXO Business Profile
Incorporated in 1924 as H J Foster and Co, Glaxo India became a wholly-owned subsidiary of Joseph Nathan and Co., UK. Later in 1947, the company was renamed as Glaxo Laboratories (India). In 2000, Glaxo Wellcome plc and SmithKline plc merged under an agreement to form a new company, named GlaxoSmithKline plc. With this merger, Glaxo India is now an affiliate of GlaxoSmithKline plc, which holds 51 per cent of the equity. Its principal products are, Betamethasone based topical steroids, Betnovate-C, Betnovate-M, and Betnovate- GM. It also makes tablets from the same pharmaceutical ingredient, which is marketed under the brand name Betnesol. Its other key products are Cephalosporin, Ceftum, H2 blocker based on Ranitidine, Zinetac and the vitamin Celin. Glaxo manufactures the bulk drug from the basic stage, furfuryl alcohol, employing the technology developed by its parent, Glaxo Wellcome, UK. The company also markets over-the-counter (OTC) medicines, dental products, smoking control products and nutritional healthcare drinks. Occupying a 6.5 per cent market share (2005), the company has Biddle Sawyer as its subsidiary. The company recently launched four new products licensed from companies in the US and Japan viz. Parit (Rabeprazole) in alliance with Eisai, Japan, Ferronine (a novel chelated iron) in alliance with Albion, USA and two new oral contraceptives in alliance with Organon. GSK plans to focus on the development of new technologies for Betamethasone, Clobetasone, Clobetasol and collaborative research work with GlaxoSmithKline - R&D, UK. The current market capitalization stands at Rs 20,328.72 crore. The company has reported a standalone sales of Rs 626.65 crore and a Net Profit of Rs 100.95 crore for the quarter ended September 2013. The company management includes D S Parekh - Chairman, V Thyagarajan - Vice Chairman, H B Joshipura - Managing Director, R R Bajaaj - Director, S Harford - Director, M B Kapadia - Director, P V Bhide - Director, R Krishnaswamy - Director, P V Nayak - Director, A N Roy - Director, R C Sequeira - Director, Anjali P Bansal - Ind. Non-Executive Director. The Registered office is at Dr. Annie Besant Road, Mumbai, Maharashtra - 400030.